Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial: Insights From the Department of Veterans Affairs
Year: 2024
Type: article
Abstract: In the recently presented ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab trial, alirocumab use in patients with acute coronary syndrome (ACS) and low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dL (or non–high-density lipoprotein cholesterol ≥100 mg/dL or apolipoprotein B ≥80 mg/dL) resulted in a 15% relative (1.6% absolute) reduction in the risk of major adverse cardiovascular events. We evaluated what proportion of patients in the VA Health Care System would qualify for alirocumab on the basis of ODYSSEY Outcomes criteria, how they are currently treated with LDL-C–lowering medications, and the cost implications if other evidence-based medications were used first before a proprotein convertase subtilisin/kexin type 9 inhibitor was considered.
DOI: 10.17615/42ma-ch89
Authors: Petersen, L.A, Ballantyne, C.M, Virani, S.S, Akeroyd, J.M, Smith, Jr., S.C, Nambi, V, Morris, P.B, Nasir, K, Michos, E.D, Stone, N.J
Institution: University of North Carolina at Chapel Hill
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: American Diabetes Association, U.S. Department of Veterans Affairs, American Heart Association, Northwestern University, Health Services Research and Development, Johns Hopkins University, University of South Carolina, University of North Carolina at Chapel Hill, Feinberg School of Medicine
Award: G823825100
OpenAlex ID: W4400026100